TENX vs VOR
TENX: A Phase 3 development-stage pharmaceutical company developing novel cardiopulmonary therapies, primarily levosimendan for pulmonary hypertension and imatinib for pulmonary arterial hypertension. VOR: Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
Side-by-side fundamentals
| Metric | TENX | VOR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $14.79 | $19.51 | |
| Market cap as of 2026-07-23 | $418M | $1.1B | |
| PEG as of 2026-07-23 | n/a | -0.00 | |
| Net margin as of 2026-07-23 | -10115.8% | n/a | |
| Gross margin as of 2026-07-23 | +100.0% | n/a | |
| Operating margin as of 2026-07-23 | -10390.5% | n/a | |
| ROE as of 2026-07-23 | -56.3% | -142.1% | TENX higher |
| ROA as of 2026-07-23 | -53.1% | -261.2% | TENX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -82.9% | n/a | |
| Beta as of 2026-07-23 | 0.95 | 1.60 | |
| 1-year return as of 2026-07-22 close | +145.7% | -51.1% | TENX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.